In two preliminary reports of studies combining sorafenib with mTOR inhibitor temsirolimus, significant toxicity was described including mucocutaneous toxicity, serum transaminase elevations, hypertrygliceridemia and thrombocytopenia (Patnaik et al, 2007; Kim et al, 2009). Here, MTOR is linked to Thrombocytopenia.